CDRE Stock Analysis: Cadre Holdings | NYSE
Aerospace & Defense | NYSE, USA | Market Cap: 1.449m USD | 12M Return: 10.5% | US12763L1052 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 11.9M
EPS Trend: 41.0%
Qual. Beats: 0
Rev. Trend: 97.7%
Qual. Beats: 1
Warnings
Tailwinds
No distinct edge detected
Seasonality 4.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Cadre Holdings, Inc. (NYSE: CDRE) is a Jacksonville, Florida-based manufacturer and distributor of personal protective and safety equipment serving both first responders and government agencies. Founded in 1964 and listed on the NYSE since its 2021 IPO, the company operates through two segments-Product and Distribution-offering body armor, bomb suits, survival suits, duty gear, communications equipment, forensic products, and crowd-control tools under brands such as Safariland and Protech Tactical, alongside third-party items including uniforms, optics, boots, firearms, and ammunition. Cadre also designs and services specialized vessels, precision components, and remote handling systems for the nuclear, defense, and oil and gas industries.
Its customers span U.S. state and local law enforcement, fire and rescue, EOD technicians, EMTs, and federal agencies including the Departments of State, Defense, Interior, Justice, Homeland Security, and Energy, as well as various foreign governments. Products reach end users through a direct sales force, distribution partners, online stores, and third-party resellers. As a small-cap Industrials company focused on mission-critical safety equipment, Cadre is positioned within the niche of protective gear suppliers that depend heavily on government procurement contracts and multi-year defense and homeland security budget cycles.
- Federal law enforcement body armor demand drives Product segment growth
- Distribution segment margins pressure overall profitability as mix shifts
- Defense and nuclear equipment orders expand from DoD and DOE contracts
| Net Income: 36.1m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.09 > 0.02 and ΔFCF/TA 4.31 > 1.0 |
| NWC/Revenue: 27.08% < 20% (prev 48.02%; Δ -20.93% < -1%) |
| CFO/TA 0.10 > 3% & CFO 88.4m > Net Income 36.1m |
| Net Debt (371.3m) to EBITDA (90.2m): 4.12 < 3 |
| Current Ratio: 2.14 > 1.5 & < 3 |
| Outstanding Shares: last quarter (43.4m) vs 12m ago 5.98% < -2% |
| Gross Margin: 40.75% > 18% (prev 41.10%; Δ -0.35% > 0.5%) |
| Asset Turnover: 80.11% > 50% (prev 72.08%; Δ 8.03% > 0%) |
| Interest Coverage Ratio: 4.34 > 6 (EBIT TTM 67.9m / Interest Expense TTM 15.7m) |
| A: 0.20 (Total Current Assets 348.1m - Total Current Liabilities 162.4m) / Total Assets 917.3m |
| B: 0.04 (Retained Earnings 39.6m / Total Assets 917.3m) |
| C: 0.08 (EBIT TTM 67.9m / Avg Total Assets 855.9m) |
| D: 0.61 (Book Value of Equity 346.8m / Total Liabilities 570.5m) |
| Altman-Z'' = 2.64 = A |
| DSRI: 0.99 (Receivables 128.4m/108.1m, Revenue 685.6m/572.6m) |
| GMI: 1.01 (GM 41.10% / 40.75%) |
| AQI: 1.17 (AQ_t 0.46 / AQ_t-1 0.39) |
| SGI: 1.20 (Revenue 685.6m / 572.6m) |
| TATA: -0.06 (NI 36.1m - CFO 88.4m) / TA 917.3m) |
| Beneish M = -2.79 (Cap -4..+1) = A |
As of August 26, 2026, the stock is trading at USD 33.08 with a total of 380,120 shares traded. Over the past week, the price has changed by -0.66%, over one month by +7.55%, over three months by +6.82% and over the past year by +10.53%.
Current recommended Stop Loss: 30.20 (which is 8.7% or 1.9 ATR below the current price).
Cadre Holdings has received a consensus analysts rating of 4.43. Therefore, it is recommended to buy CDRE.
- StrongBuy: 4
- Buy: 2
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 44.4 | 34.3% |
P/E Trailing = 42.3125
P/E Forward = 26.455
P/S = 2.114
P/B = 4.2154
Revenue TTM = 685.6m USD
EBIT TTM = 67.9m USD
EBITDA TTM = 90.2m USD
Long Term Debt = 354.3m USD (from longTermDebt, last quarter)
Short Term Debt = 28.3m USD (from shortTermDebt, last quarter)
Debt = 425.3m USD (from shortLongTermDebtTotal, last quarter) + Leases 25.5m
Net Debt = 371.3m USD (calculated: Debt 425.3m - CCE 54.0m)
Enterprise Value = 1.82b USD (1.45b + Debt 425.3m - CCE 54.0m)
Interest Coverage Ratio = 4.34 (Ebit TTM 67.9m / Interest Expense TTM 15.7m)
EV/FCF = 23.31x (Enterprise Value 1.82b / FCF TTM 78.1m)
FCF Yield = 4.29% (FCF TTM 78.1m / Enterprise Value 1.82b)
FCF Margin = 11.39% (FCF TTM 78.1m / Revenue TTM 685.6m)
Net Margin = 5.26% (Net Income TTM 36.1m / Revenue TTM 685.6m)
Gross Margin = 40.75% ((Revenue TTM 685.6m - Cost of Revenue TTM 406.3m) / Revenue TTM)
Gross Margin QoQ = 42.07% (prev 37.73%)
Tobins Q-Ratio = 1.98 (Enterprise Value 1.82b / Total Assets 917.3m)
Interest Expense / Debt = 3.68% (Interest Expense 15.7m / Debt 425.3m)
Taxrate = 30.99% (16.2m / 52.3m)
NOPAT = 46.9m (EBIT 67.9m * (1 - 30.99%))
Current Ratio = 2.14 (Total Current Assets 348.1m / Total Current Liabilities 162.4m)
Debt / Equity = 1.23 (Debt 425.3m / totalStockholderEquity, last quarter 346.8m)
Debt / EBITDA = 4.12 (Net Debt 371.3m / EBITDA 90.2m)
Debt / FCF = 4.75 (Net Debt 371.3m / FCF TTM 78.1m)
Total Stockholder Equity = 335.3m (last 4 quarters mean from totalStockholderEquity)
RoA = 4.21% (Net Income 36.1m / Total Assets 917.3m)
RoE = 10.76% (Net Income TTM 36.1m / Total Stockholder Equity 335.3m)
RoCE = 9.85% (EBIT 67.9m / Capital Employed (Equity 335.3m + L.T.Debt 354.3m))
RoIC = 6.26% (NOPAT 46.9m / Invested Capital 748.9m)
WACC = 6.65% (E(1.45b)/V(1.87b) * Re(7.86%) + D(425.3m)/V(1.87b) * Rd(3.68%) * (1-Tc(0.31)))
Discount Rate = 7.86% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 87.96 | Cagr: 5.39%
[DCF] Terminal Value 77.97% ; FCFF base≈60.2m ; Y1≈69.1m ; Y5≈101.6m
[DCF] Fair Price = 27.05 (EV 1.53b - Net Debt 371.3m = Equity 1.16b / Shares 42.8m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 41.03 | EPS CAGR: 4.54% | SUE: -0.29 | # QB: 0
Revenue Correlation: 97.69 | Revenue CAGR: 12.94% | SUE: 3.97 | # QB: 1
EPS current Quarter (2026-09-30): EPS=0.34 | Chg30d=-16.03% | Revisions=+0% | Analysts=2
EPS current Year (2026-12-31): EPS=1.42 | Chg30d=+6.13% | Revisions=+0% | GrowthEPS=+30.6% | GrowthRev=+22.1%
EPS next Year (2027-12-31): EPS=1.68 | Chg30d=+25.07% | Revisions=+0% | GrowthEPS=+17.9% | GrowthRev=+8.6%
[Analyst] Revisions Ratio: +0% (up=0, down=0)